Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MMP12 | P39900 | 3/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22887031 | 0.95 | LMNA (0.33) | CYP3A4MAPTCYP2C9CYP2C19LMNA | |
| SCHEMBL22855480 | 0.93 | CYP3A4 (0.32) | CYP3A4MAPTCYP2C9CYP2C19LMNA | |
| SCHEMBL26737801 | 0.90 | CYP3A4 (0.30) | CYP3A4MAPTCYP2C9CYP2C19LMNA | |
| SCHEMBL22830076 | 0.89 | — | — | |
| SCHEMBL22855532 | 0.87 | LMNA (0.38) | CYP3A4MAPTCYP2C9CYP2C19LMNA | |
| SCHEMBL21344301 | 0.85 | — | — | |
| SCHEMBL22855650 | 0.85 | LMNA (0.36) | CYP3A4MAPTCYP2C9CYP2C19LMNA | |
| SCHEMBL22855462 | 0.84 | LMNA (0.34) | CYP3A4MAPTCYP2C9CYP2C19LMNA | |
| SCHEMBL29934231 | 0.84 | — | — | |
| SCHEMBL22830131 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378920-A1 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-01 | — | — | US | disclosed |
| EP-3763815-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | Daiichi Sankyo Company, Limited (JP) | 2021-01-13 | — | — | EP | disclosed |
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | G6PC1, GAA, GBA3 | CYP3A4 4459/4885MAPT 863/4885CYP2C9 4405/4885 |
| US-20220378920-A1 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | CSGALNACT1, GALNT6, GALNT14 | CYP3A4 2402/4885MAPT 2758/4885CYP2C9 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.